Genotype

Bolverk VR Games · 2024 · $24.99 · Action · deal grade B

Measured on 2026-09-21 17:42 UTC, 14 days ago. The whole catalog is re-measured daily; a game that just launched can move fast between passes.

Estimated net residual revenue: $184 to $276 per month
Opportunity: $437 per month at x1.90 dormancy
Estimated lifetime owners: 1.7k
92% positive across 50 reviews · 1.3 reviews/month

Why it's flagged

Developer silent for 2.3 years
Studio quiet across its whole catalog
Last build shipped 28 months ago

Analyst notes (AI-assisted)

Note written 2026-09-19; the live figures above take precedence over any numbers in it.

Genotype is a single-player action game built around a unique core mechanic, released in 2024 to strong critical reception but minimal visibility.

Genotype sits at an interesting inflection point: 92% positive reviews and solid median playtime suggest strong design fundamentals, yet the title is earning quiet residuals with essentially no active player base and zero promotional activity in its first 28 months. The developer (Bolverk VR Games, now fading) has not posted updates or engaged with the community since launch. For a publisher or platform-focused acquirer, this represents a low-cost catalog addition with proven creative merit and room to surface via modest marketing or bundling; revival is viable only if the developer's intent and capacity can be clarified first. Most realistic play: acquisition.

Risk: Developer studio is listed as 'fading' with no activity logged since launch; code maintenance and live-ops support will fall entirely to the acquirer.
Risk: Despite strong review scores, the title has attracted a mid-sized owner base and generated only 1-2 reviews per month; discovery or audience fit may be structurally limited.
Risk: Localization gap of 13% suggests untapped revenue potential in Russian-speaking markets, but requires translation investment and regional marketing.

This case as Markdown · Estimates carry ±30-50% error per title.